Abstract
Community-acquired pneumonia (CAP) accounts for major morbidity and mortality in the United States. With improved broad-spectrum antibiotics, the implementation of diagnostic studies has declined and most patients do not have an etiologic pathogen of CAP identified. To enhance the appropriate use of antiviral agents and prevent overuse of antibiotics, the successful management of CAP requires rapid and accurate diagnosis of the etiologic agent of CAP. This article provides an overview of the new rapid molecular tests for the diagnosis of influenza, other respiratory viruses, and bacteria compared with nonmolecular tests and how their use for directed therapy can enhance and improve the management of CAP.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 49-69 |
| Number of pages | 21 |
| Journal | Infectious disease clinics of North America |
| Volume | 27 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2013 |
Keywords
- Community-acquired pneumonia
- Diagnosis
- Influenza
- PCR
- Point-of-care tests
- Respiratory bacteria
- Respiratory viruses
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases